The CHARM trial programme asked the question: should angiotensin receptor antagonists be given to patients with heart failure who are already taking angiotensin-converting enzyme inhibitors (ACE inhibitors)?
There were three individual trials:
These trials showed that, in patients with chronic heart failure, the angiotensin receptor blocker candesartan led to a reduction in mortality (especially cardiovascular) and hospital admissions for worsening chronic heart failure. The most benefit was seen in patient with reduced left ventricular ejection fraction with or without baseline angiotensin converting enzyme inhibitor treatment.
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.